Breaking News

IDIFARMA Gains Authorization for New Dosage Forms

By Kristin Brooks | January 13, 2014

Expanded GMP capabilities include powders, tablets, and hard capsules

IDIFARMA has obtained an extension of its authorization as a GMP clinical manufacturer by the Spanish Medicines Agency (AEMPS) to include new dosage forms. The expanded GMP capabilities allow for the manufacture of powders for oral use (including powders for oral solutions and suspensions), as well as tablets and hard capsules. IDIFARMA has also adapted its lab authorization to the new European format for manufacturing, including GMP over-encapsulation to blind solid dosage forms for double-blind trials.
The company is also GMP-certified to provide primary and secondary packaging services, quality control testing and QP release, storage, shipment and destruction of medication, as well as services such as blinding strategies, placebo manufacturing, stability studies, and regulatory affairs. IDIFARMA’s high containment development and manufacturing facilities are authorized to handle high potency compounds, as well as humidity-controlled conditions with organic or water solvents.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • Drug Supply Shortages in Clinical Trials

    Drug Supply Shortages in Clinical Trials

    John Burns , BioClinica||November 13, 2014
    Impacts on studies and how to avoid them.

  • Clinical Trial Supplies 101: Outsourcing Primer for Virtual Pharma and Biopharma Companies, Part II

    Clinical Trial Supplies 101: Outsourcing Primer for Virtual Pharma and Biopharma Companies, Part II

    Alex McClung, Xcelience||November 13, 2014
    Getting packaged investigational materials dispensed to the patients taking part in clinical trials, on time and correctly, requires orchestrating myriad activities. This is the second in a series of articles outlining specific quality concerns associated with packaging clinical trial supplies and how to effectively manage those concerns.